Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer

Sponsor
National Cancer Center, Korea
Study ID
NCT00506844
Phase
PHASE2
Status
Unknown

Conditions

  • Neoadjuvant Treatment
  • Rectal Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is to estimate the pathologic complete response rate of cetuximab, irinotecan, and capecitabine concurrent with radiotherapy given preoperatively in patients with resectable rectal cancer.

Key Dates

Start date
May 31, 2006
Status verified
Jul 2007
Completion
May 31, 2010

Study Design

Enrollment
40 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Pathologic stage Tumor regression grade [ Time Frame: After operation ]

Related Studies